Amgen, J&J settle ustekinumab patent lawsuit in potential biosimilar market shake-up
Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing. Meanwhile, the rheumatology world awaits the debut of other ustekinumab biosimilars in the market — and what they may portend for patient care moving forward
Source: healio.com